Shares of Johnson & Johnson (NYSE:JNJ) have received a consensus recommendation of “Hold” from the twenty-one ratings firms that are presently covering the company, Marketbeat reports. Five analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $133.79.
JNJ has been the topic of several research analyst reports. Credit Suisse Group reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Friday, August 4th. Vetr cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 price target on the stock. in a research note on Monday. Alembic Global Advisors cut shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research note on Friday, July 21st. UBS AG reiterated a “buy” rating and issued a $148.00 price target on shares of Johnson & Johnson in a research note on Thursday, August 31st. Finally, Wells Fargo & Company reiterated a “market perform” rating and issued a $135.00 price target (up previously from $132.00) on shares of Johnson & Johnson in a research note on Thursday, July 6th.
In related news, VP Paulus Stoffels sold 102,692 shares of the stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the sale, the vice president now directly owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of the stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the sale, the vice president now directly owns 226,693 shares in the company, valued at $30,993,466.96. The disclosure for this sale can be found here. Corporate insiders own 0.19% of the company’s stock.
Institutional investors have recently bought and sold shares of the stock. Harding Loevner LP purchased a new stake in Johnson & Johnson in the 2nd quarter worth about $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its position in Johnson & Johnson by 29.9% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares during the period. Lenox Wealth Advisors Inc. raised its position in Johnson & Johnson by 0.7% in the 1st quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock worth $108,000 after purchasing an additional 6 shares during the period. Mountain Capital Investment Advisors Inc purchased a new stake in Johnson & Johnson in the 2nd quarter worth about $124,000. Finally, Harel Insurance Investments & Financial Services Ltd. raised its position in Johnson & Johnson by 241.0% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock worth $149,000 after purchasing an additional 841 shares during the period. 65.90% of the stock is currently owned by institutional investors.
Shares of Johnson & Johnson (NYSE:JNJ) traded down 1.48% during midday trading on Friday, hitting $133.22. The company had a trading volume of 8,705,535 shares. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $137.08. The firm has a market capitalization of $357.56 billion, a P/E ratio of 22.54 and a beta of 0.79. The stock has a 50 day moving average price of $132.79 and a 200 day moving average price of $129.43.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.04. The company had revenue of $18.84 billion during the quarter, compared to the consensus estimate of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. Johnson & Johnson’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.74 EPS. On average, equities analysts anticipate that Johnson & Johnson will post $7.18 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th were given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 2.52%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 56.76%.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.